The U.S. FDA approved Takeda Pharmaceutical Co. Ltd.’s Fruzaqla (fruquintinib) nearly 20 days ahead of its Nov. 30 PDUFA date for adults with previously treated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback